Omentin-1 and risk of myocardial infarction and stroke: Results from the EPIC-Potsdam cohort study

Atherosclerosis

Volumn 251, Issue , 2016, Pages 415-421

  Menzel, Juliane ^a,b,c   di Giuseppe, Romina ^a,d   Biemann, Ronald ^e   Wittenbecher, Clemens ^a,c   Aleksandrova, Krasimira ^a   Pischon, Tobias ^f,g   Fritsche, Andreas ^c,h   Schulze, Matthias B ^a,c,g   Boeing, Heiner ^a   Isermann, Berend ^e   Weikert, Cornelia ^a,b,g,i  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

^f MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^g DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^h UNIVERSITY OF TÜBINGEN   (Germany)

ⁱ FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

Author keywords

Adipokines; Adiponectin; Intelectin 1; Risk factor

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; OMENTIN 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ADIPOQ PROTEIN, HUMAN; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN;

ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; METABOLISM; MULTIVARIATE ANALYSIS; PHYSIOLOGY; RISK FACTOR;

ADIPOKINES; ADIPONECTIN; C-REACTIVE PROTEIN; COHORT STUDIES; CYTOKINES; FEMALE; GPI-LINKED PROTEINS; HUMANS; LECTINS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; RISK FACTORS; STROKE; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 85006810534     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.06.003     Document Type: Article

References (41)

1. [1] Yang, R.Z., Lee, M.J., Hu, H., et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab. 290 (2006), E1253–E1261.
2. [2] Tan, B.K., Adya, R., Randeva, H.S., Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc. Med. 20 (2010), 143–148.
3. [3] de Souza Batista, C.M., Yang, R.Z., Lee, M.J., et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56 (2007), 1655–1661.
4. [4] Liu, R., Wang, X., Bu, P., Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res. Clin. Pract. 93 (2011), 21–25.
5. [5] Greulich, S., Chen, W.J., Maxhera, B., et al. Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PLoS One, 8, 2013, e59697.
6. [6] Zhong, X., Zhang, H.Y., Tan, H., et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol. Sin. 32 (2011), 873–878.
7. [7] Shang, F.J., Wang, J.P., Liu, X.T., et al. Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers 16 (2011), 657–662.
8. [8] Onur, I., Oz, F., Yildiz, S., et al. Serum omentin 1 level is associated with coronary artery disease and its severity in postmenopausal women. Angiology 65 (2014), 896–900.
9. [9] Shibata, R., Ouchi, N., Kikuchi, R., et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis 219 (2011), 811–814.
10. [10] Wang, X.H., Dou, L.Z., Gu, C., et al. Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure. Asian Pac. J. Trop. Med. 7 (2014), 55–62.
11. [11] Boeing, H., Wahrendorf, J., Becker, N., EPIC-Germany–A source for studies into diet and risk of chronic diseases. Eur. Investig. Cancer Nutr. Ann. Nutr. Metab. 43 (1999), 195–204.
12. [12] Weikert, C., Stefan, N., Schulze, M.B., et al. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 118 (2008), 2555–2562.
13. [13] Weikert, C., Berger, K., Heidemann, C., et al. Joint effects of risk factors for stroke and transient ischemic attack in a German population: the EPIC Potsdam study. J. Neurol. 254 (2007), 315–321.
14. [14] Weikert, C., Drogan, D., di Giuseppe, R., et al. Liver enzymes and stroke risk in middle-aged German adults. Atherosclerosis 228 (2013), 508–514.
15. [15] Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., et al. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 90 (1994), 583–612.
16. [16] World Health Organization, International Statistical Classification of Diseases and Related Health Problems. 1992, World Health Organization, Geneva, Switzerland.
17. [17] Prentice, R.L., A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73 (1986), 1–11.
18. [18] Lunn, M., McNeil, D., Applying Cox regression to competing risks. Biometrics 51 (1995), 524–532.
19. [19] Grundy, S.M., Brewer, H.B. Jr., Cleeman, J.I., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004), 433–438.
20. [20] Fischbach, F.T., Dunning, M.B. III, Manual of laboratory and diagnostic tests. Lippincott Williams Wilkins 8 (2009), 642–643.
21. [21] Narumi, T., Watanabe, T., Kadowaki, S., et al. Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure. Cardiovasc Diabetol., 13, 2014, 84.
22. [22] Saely, C.H., Leiherer, A., Muendlein, A., et al. High plasma omentin predicts cardiovascular events independently from the presence and extent of angiographically determined atherosclerosis. Atherosclerosis, 2015, 10.1016/j.atherosclerosis.2015.10.100.
23. [23] Saely, C.H., Leiherer, A., Muendlein, A., et al. Coronary patients with high plasma omentin are at a higher cardiovascular risk. Data Brief 6 (2016), 158–161.
24. [24] Herder, C., Ouwens, D.M., Carstensen, M., et al. Adiponectin may mediate the association between omentin, circulating lipids and insulin sensitivity: results from the KORA F4 study. Eur. J. Endocrinol./Eur. Fed. Endocr. Soc. 172 (2015), 423–432.
25. [25] Jialal, I., Devaraj, S., Kaur, H., et al. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J. Clin. Endocrinol. Metab. 98 (2013), E514–E517.
26. [26] Yan, P., Liu, D., Long, M., et al. Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes Off. J. Ger. Soc. Endocrinol. Ger. Diabetes Assoc. 119 (2011), 257–263.
27. [27] Yoo, H.J., Hwang, S.Y., Hong, H.C., et al. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol., 10, 2011, 103.
28. [28] Caselli, C., D'Amico, A., Cabiati, M., et al. Back to the heart: the protective role of adiponectin. Pharmacol. Res. Off. J. Ital. Pharmacol. Soc. 82 (2014), 9–20.
29. [29] Park, S.E., Park, C.Y., Sweeney, G., Biomarkers of insulin sensitivity and insulin resistance: past, present and future. Crit. Rev. Clin. Lab. Sci., 2015, 1–11.
30. [30] Zhu, W., Cheng, K.K., Vanhoutte, P.M., et al. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin. Sci. 114 (2008), 361–374.
31. [31] Yamawaki, H., Tsubaki, N., Mukohda, M., et al. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem. Biophys. Res. Commun. 393 (2010), 668–672.
32. [32] Maruyama, S., Shibata, R., Kikuchi, R., et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J. Biol. Chem. 287 (2012), 408–417.
33. [33] Kataoka, Y., Shibata, R., Ohashi, K., et al. Omentin prevents myocardial ischemic injury through AMP-activated protein kinase- and Akt-dependent mechanisms. J. Am. Coll. Cardiol. 63 (2014), 2722–2733.
34. [34] Uemura, Y., Shibata, R., Kanemura, N., et al. Adipose-derived protein omentin prevents neointimal formation after arterial injury. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 29 (2015), 141–151.
35. [35] Kazama, K., Usui, T., Okada, M., et al. Omentin plays an anti-inflammatory role through inhibition of TNF-alpha-induced superoxide production in vascular smooth muscle cells. Eur. J. Pharmacol. 686 (2012), 116–123.
36. [36] Yamawaki, H., Kuramoto, J., Kameshima, S., et al. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem. Biophys. Res. Commun. 408 (2011), 339–343.
37. [37] Ohashi, K., Shibata, R., Murohara, T., et al. Role of anti-inflammatory adipokines in obesity-related diseases. Trends Endocrinol. Metab. TEM 25 (2014), 348–355.
38. [38] Elliott, P., Peakman, T.C., Biobank, U.K., The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int. J. Epidemiol. 37 (2008), 234–244.
39. [39] Lewis, M.R., Callas, P.W., Jenny, N.S., et al. Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb. Haemost. 86 (2001), 1495–1500.
40. [40] Panagiotou, G., Mu, L., Na, B., et al. Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk. Metabolism 63 (2014), 1265–1271.
41. [41] Wittenbecher, C., di Giuseppe, R., Biemann, R., et al. Reproducibility of retinol binding protein 4 and omentin-1 measurements over a four months period: a reliability study in a cohort of 207 apparently healthy participants. PLoS One, 10, 2015, e0138480.